SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

World Journal of Diabetes
Henith RajJayaprakash Sahoo

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD. Pioglitazone is the only drug recommended in diabetes patients with biopsy proven non-alcoholic steatohepatitis. The frequent coexistence of NAFLD and type 2 diabetes with their combined adverse health consequences and inadequate therapeutic options makes it necessary to search for newer alternatives. To assess the effect of sodium glucose cotransporter-2 (SGLT-2) inhibitors on liver enzymes in type 2 diabetes patients with NAFLD. We searched PubMed/MEDLINE, Cochrane library, Google scholar, and Clinicaltrials.gov for the relevant articles to be included in this systematic review. Human studies done in type 2 diabetes patients with NAFLD treated with SGLT-2 inhibitors for at least 12 wk were included. Data from eight studies (four randomised controlled trials and four observational studies) were extracted and a narrative synthesis was done. A total of 214 patients were treated with SGLT-2 inhibitors in these studies (94 in randomised controlled trials and 120 in observational studies). The primary outcome measure...Continue Reading

References

Mar 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Paul AnguloChristopher P Day
Jun 16, 2009·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Amy G ShahUNKNOWN Nash Clinical Research Network
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Dec 15, 2012·Endocrine Reviews·K H WilliamsS M Twigg
Nov 27, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra
Apr 22, 2015·Current Diabetes Reports·Chiara SaponaroAmalia Gastaldelli
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Sep 18, 2015·Seminars in Liver Disease·Alastair D BurtDina G Tiniakos
Dec 3, 2015·Journal of Clinical and Experimental Hepatology·Shigeru NakanoBentley Cheatham
May 24, 2016·International Journal of Molecular Sciences·Luis Calzadilla Bertot, Leon Anton Adams
Jul 21, 2016·JAMA : the Journal of the American Medical Association·Suetonia C PalmerGiovanni F M Strippoli
Dec 8, 2016·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yuya SekoYoshito Itoh
Jul 18, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Naga ChalasaniArun J Sanyal
May 21, 2018·Journal of the National Medical Association·Babalola Ishmael AfolabiDavid Olubukunmi Soyoye
Jun 8, 2018·Nature Reviews. Nephrology·Jenny E Blau, Simeon I Taylor
Jul 28, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yoshio SumidaTakeshi Osonoi

❮ Previous
Next ❯

Citations

Dec 17, 2019·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Manpreet S MundiRyan T Hurt
Feb 19, 2020·Diabetes Technology & Therapeutics·Satish K GargIrl B Hirsch
Jul 23, 2020·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Philipp KasperHans-Michael Steffen
Jul 21, 2020·Diabetology & Metabolic Syndrome·Amélio F Godoy-MatosCynthia M Valerio
Oct 4, 2020·Diabetes/metabolism Research and Reviews·Francisca Dos Santos CoelhoAdelino Leite-Moreira
Nov 28, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mario Simental-MendíaLuis E Simental-Mendía
Feb 2, 2021·World Journal of Diabetes·Zuo-Di FuYu-Feng Li
Mar 30, 2021·International Journal of General Medicine·Amy W RachfalStanley S Schwartz
Dec 16, 2020·Clinical and Molecular Hepatology·Karn WijarnpreechaDonghee Kim
Jun 3, 2021·Journal of Clinical Medicine·Carolina M PerdomoJavier Escalada
Jun 21, 2021·European Journal of Pharmacology·Evangelia S MakriStergios A Polyzos

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

Cochrane
PROSPERO

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.